How big is GeneDx Holdings Corp.?

As of Jun 18, GeneDx Holdings Corp. has a market capitalization of $1.83 billion, with net sales of $330.13 million and a net profit of -$38.57 million over the last four quarters.

Market Cap: As of Jun 18, GeneDx Holdings Corp. has a market capitalization of 1,827.27 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, GeneDx Holdings Corp. reported net sales of 330.13 million and a net profit of -38.57 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 245.25 million and total assets of 464.70 million.

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $87 million and a net loss of $7 million as of March 2025. It has a market cap of $1.83 billion and does not pay dividends.

Overview:<BR>GeneDx Holdings Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 87 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,827.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.40 <BR>Return on Equity: -11.17% <BR>Price to Book: 7.10<BR><BR>Contact Details:<BR>Address: C/O Corvex Management Lp, 667 Madison Avenue NEW YORK NY : 10020 <BR>Tel: 1 212 4746700 <BR>Fax: 1 302 6365454 <BR>Website: https://cmlifesciencesspac.com/

Should I buy, sell or hold GeneDx Holdings Corp.?

Is GeneDx Holdings Corp. overvalued or undervalued?

As of October 17, 2025, GeneDx Holdings Corp. is considered undervalued with attractive valuation metrics despite a negative P/E ratio, showing significant growth potential compared to peers like Aveanna Healthcare, and has outperformed the S&P 500 with a 115.96% return over the past year.

As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a significant shift in its perceived value. The company appears undervalued, particularly when considering its Price to Book Value of 7.99 and an EV to Sales ratio of 5.92. Despite its negative P/E ratio due to losses, the EV to EBITDA ratio stands at a high 188.80, suggesting that the market may be pricing in future growth potential that has yet to materialize.<BR><BR>In comparison to its peers, GeneDx's valuation metrics are strikingly different; for instance, Aveanna Healthcare Holdings, Inc. has a P/E ratio of 31.16 and an EV to EBITDA of 12.45, reflecting a more traditional valuation approach. The substantial difference in these ratios highlights GeneDx's current market position. Over the past year, GeneDx has outperformed the S&P 500 with a return of 115.96% compared to the index's 14.08%, reinforcing the notion that the stock may be undervalued relative to its growth trajectory.

Is GeneDx Holdings Corp. technically bullish or bearish?

As of October 24, 2025, GeneDx Holdings Corp. shows a bullish technical trend, supported by daily moving averages and Bollinger Bands, despite some mixed signals from MACD and Dow Theory, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish and the monthly MACD is bullish. Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish signal weekly but is mildly bearish monthly. Dow Theory indicates a mildly bearish trend weekly with no trend monthly. The OBV is mildly bullish on both time frames.<BR><BR>GeneDx has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 67.67% compared to the S&P 500's 15.47%, and a one-year return of 118.09% versus 16.90%. Overall, the current technical stance is bullish, driven primarily by the daily moving averages and the bullish Bollinger Bands.